{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"88.2","upperLimit":"94.5","value":"91.7"},{"groupId":"OG001","lowerLimit":"78.5","upperLimit":"87.0","value":"83.1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"327"},{"groupId":"OG001","value":"325"}],"units":"Participants"}],"description":"The rate of partial response with lymphocytosis or better is defined as the percentage of participants who achieved a complete response or a complete response with incomplete bone marrow recovery (CR/CRi), nodular partial response, partial response, or partial response with lymphocytosis assessed by the blinded IRC.\n\nDisease response was assessed per iwCLL 2008 criteria, with modification for treatment-related lymphocytosis for participants with CLL and per Lugano classification for participants with SLL.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received 160 mg zanubrutinib orally twice daily until disease progression, intolerable toxicity, initiation of alternative anticancer therapy, investigator/Sponsor decision, need for prohibited medication, study withdrawal, or pregnancy.","id":"OG000","title":"Zanubrutinib"},{"description":"Participants received ibrutinib 420 mg orally once daily until disease progression, intolerable toxicity, initiation of alternative anticancer therapy, investigator/Sponsor decision, need for prohibited medication, study withdrawal, or pregnancy.","id":"OG001","title":"Ibrutinib"}],"paramType":"NUMBER","populationDescription":"ITT Analysis Set","reportingStatus":"POSTED","timeFrame":"From randomization to the final efficacy analysis cutoff date of 08 August 2022, median time on follow-up was 29.6 months (maximum of 45.2 months).","title":"Rate of Partial Response With Lymphocytosis (PR-L) or Higher Assessed by the Independent Review Committee","type":"SECONDARY","unitOfMeasure":"percentage of participants"}